Newsbenzinga
Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
· Published
Article summary
Sionna Therapeutics topline clinical data for cystic fibrosis programs disappoints, opting to discontinue its SION-719 candidate.
An excerpt from the original article.
Comments —
Loading comments…